期刊
DRUG DESIGN DEVELOPMENT AND THERAPY
卷 9, 期 -, 页码 4303-4318出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S86105
关键词
nab-paclitaxel; paclitaxel; docetaxel; bevacizumab
资金
- Editree, Italy
Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs. In this review, data on the use of taxanes in triple-negative BCs are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and metastatic). Further, the role of nab-paclitaxel (formulation of albumin-bound paclitaxel) in these tumors is also evaluated. The available data show the clinical potential of nab-paclitaxel based combinations in terms of long-duration response, increased survival, and better quality of life of patients with triple-negative metastatic BC. The ongoing trials will give further information on the better management of this type of tumor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据